Conditions: Parkinson's Disease
Keywords: Rotigotine NEUPRO Switching trial from ropinirole to rotigotine, safety and tolerability Parkinson disease
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 124
Healthy volunteers: yes

Brief summary:
This is a Phase 3b, open-label, multicenter trial to assess the safety and tolerability of switching from ropinirole therapy to the rotigotine transdermal system and its effect on symptoms in subjects with idiopathic Parkinson's disease

Detailed description:

Arms:
arm 1: Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.

Interventions: intervention 1: Rotigotine
Intervention descriptions: intervention 1: Strength: 2,4,6,and 8mg/24h, form: transdermal application, once daily application

Protocol document: